Venkatesan M, Smith R P, Balasubramanian S, Khan A, Uzoigwe C E, Coats T J, Godsiff S
Department of Trauma & Orthopaedics, University Hospitals of Leicester, Leicester, United Kingdom.
Department of Trauma & Orthopaedics, University Hospitals of Leicester, Leicester, United Kingdom.
Injury. 2015 Nov;46(11):2201-5. doi: 10.1016/j.injury.2015.06.038. Epub 2015 Jul 6.
Outcomes from patients suffering hip fracture remain poor, with 9% mortality at 30 days and 35% at 1 year. Despite robust guidelines these mortality rates have undergone little change. Admission serum lactate in patients with sepsis or suffering general trauma has been shown to be an indicator of adverse clinical outcomes. We investigated whether venous lactate can predict mortality for hip fracture patients. Over a 12-month period the admission venous lactate of all patients presenting to our institution with hip fractures was prospectively collated. Demographic and patient survivorship data were also prospectively recorded. Multivariate binary logistic regression and Cox proportional hazards ratio analysis was used to evaluate the relationship between admission venous lactate and 30-day mortality and early survivorship, whilst adjusting for age and gender. 770 patients were included in the study. The mean age was 80 years. The overall 30-day mortality for this cohort was 9.5%. Admission venous lactate was associated with early death. A 1mmol/L increase in venous lactate resulted in a 1.9 (95% CI 1.5-2.3 p<0.0001) fold increase in the odds of 30-day mortality and a 1.4 (95% CI: 1.2-1.6 p<0.0001) factor increase in the risk of death at any time after hip fracture. Admission venous lactate remained a predictor of mortality despite adjustment for patients American Society of Anesthesiologists (ASA) grade. Those with an admission serum lactate of 3mmol/L or greater were particularly at risk. This cohort had a 30-day mortality odds that was 5-fold higher than those whose level was less than 3mmol/L (p<0.0001) and at any-time risk of death that was 1.9 times higher (p<0.0001). Those with a level of less than 3mmol/L had a 30-day mortality of 6.8%. For those with an admission venous lactate of 3mmol/L or greater this was four times higher at 28%. The difference was statistically significant (p<0.0001). Elevated admission venous lactate following hip fracture is a predictor of early death. Venous lactate may be useful as a prognostic indicator or risk stratifier in patients with proximal femoral fractures.
髋部骨折患者的预后仍然很差,30天死亡率为9%,1年死亡率为35%。尽管有完善的指南,但这些死亡率几乎没有变化。脓毒症或全身创伤患者的入院血清乳酸已被证明是不良临床结局的一个指标。我们调查了静脉血乳酸是否能预测髋部骨折患者的死亡率。在12个月的时间里,前瞻性收集了所有因髋部骨折前来我院就诊患者的入院静脉血乳酸水平。还前瞻性记录了人口统计学和患者生存数据。采用多变量二元逻辑回归和Cox比例风险比分析来评估入院静脉血乳酸与30天死亡率及早期生存率之间的关系,同时对年龄和性别进行校正。770例患者纳入研究。平均年龄为80岁。该队列的总体30天死亡率为9.5%。入院静脉血乳酸与早期死亡相关。静脉血乳酸每升高1mmol/L,30天死亡几率增加1.9倍(95%可信区间1.5 - 2.3,p<0.0001),髋部骨折后任何时间的死亡风险增加1.4倍(95%可信区间:1.2 - 1.6,p<0.0001)。尽管对患者的美国麻醉医师协会(ASA)分级进行了校正,入院静脉血乳酸仍然是死亡率的一个预测指标。入院血清乳酸水平为3mmol/L或更高的患者尤其危险。该队列的30天死亡几率比乳酸水平低于3mmol/L的患者高5倍(p<0.0001),任何时间的死亡风险高1.9倍(p<0.0001)。乳酸水平低于3mmol/L的患者30天死亡率为6.8%。入院静脉血乳酸水平为3mmol/L或更高的患者,这一比例高达28%,是前者的四倍。差异具有统计学意义(p<0.0001)。髋部骨折后入院静脉血乳酸升高是早期死亡的一个预测指标。静脉血乳酸可能作为股骨近端骨折患者的预后指标或风险分层工具。